{
  "docId": "019de074-ac90-73cc-861b-68f2ee02d519",
  "docSlug": "5e6566e4cd37b5a4c67661e229e01a81",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 41 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 41,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_messages",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a stacked bar chart for Soliris registry data and a trial design schematic for gefurulimab.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ac90-73cc-861b-68f2ee02d519/26",
  "deckHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519",
  "deckJsonHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519.json",
  "deckAnchorHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.55,
        "y": 0.82
      },
      "kind": "callout",
      "text": "Potential best-in-class weekly, self-admin s.c.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03a7add5-4e78-4236-9ec5-37750b35e50e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.35,
        "x": 0.14,
        "y": 0.82
      },
      "kind": "callout",
      "text": ">75% patients on low-dose OCS after 1 year",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dad52d2f-10fa-4a22-8f90-e080989de39c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.14,
        "y": 0.225
      },
      "kind": "chart",
      "text": "Soliris gMG registry oral corticosteroid usage decreased over time",
      "attrs": null,
      "subkind": "bar-stacked-100pct",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "db93aa35-781f-43d4-840d-0724c13c1eab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.55,
        "y": 0.55
      },
      "kind": "diagram",
      "text": "Phase III PREVAIL in gMG trial design",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32771371-cad2-4d4e-a2a5-56b229307052",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.55,
        "y": 0.24
      },
      "kind": "paragraph",
      "text": "gefurulimab (ALXN1720) pipeline expansion to further extend C5 leadership",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2fde2dc6-00ea-45a3-9afb-7e558a1c94c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.95,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Pulley et al. American Academy of Neurology Annual Meeting 2023 based on Soliris data...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94bea77c-8d06-43d7-ae1c-39a0ab9060f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Pioneering in rare neurology to improve patient outcomes",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b55a19d-ab76-45af-ae01-3ab2ae78feed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Rare Disease – R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ceae94a-5077-479a-b340-515dc1cc4f6f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 26,
      "from": 10,
      "beatId": "65085a95-2c38-4ee7-a364-a6a8cc62f676",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The slides showcasing progress in Oncology, BioPharmaceuticals, and Rare Disease provide satisfaction and demonstrate the company's growth",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}